Neuromuscular Junction

NMJ Structure - Synaptic Setup

• Presynaptic Terminal (Axon Bouton):
  • Synaptic vesicles (~50 nm diameter) with Acetylcholine (ACh).
  • Active zones: aligned with postsynaptic folds for ACh release.
  • Voltage-gated Ca²⁺ channels (VGCCs) trigger exocytosis.
• Synaptic Cleft:
  • Gap: 20-50 nm wide.
  • Basal lamina: extracellular matrix containing Acetylcholinesterase (AChE).
• Postsynaptic Membrane (Motor End Plate on Sarcolemma):
  • Junctional folds: ↑ surface area for nAChRs.
  • Nicotinic ACh Receptors (nAChRs): ligand-gated ion channels, concentrated at crests of folds.
  • Voltage-gated Na⁺ channels (VGSCs): located in depths of folds, crucial for action potential propagation.

⭐ Acetylcholinesterase (AChE) is concentrated in the basal lamina within the synaptic cleft, ensuring rapid termination of ACh action and preventing continuous muscle stimulation.

ACh Synthesis & Release - Pre-Synaptic Saga

• Synthesis (Cytoplasm):

  • Choline + Acetyl CoA $\xrightarrow{Choline Acetyltransferase (ChAT)}$ Acetylcholine (ACh).
  • Rate-limiting step: Choline uptake by Na⁺-Choline Transporter 1 (CHT1). 📌 ChATs make ACh, CHT1 brings in Choline.

• Storage (Synaptic Vesicles):

  • ACh actively concentrated into vesicles by Vesicular ACh Transporter (VAChT) using H⁺ gradient.
  • Each vesicle: ~5,000-10,000 ACh molecules (one quantum).

• Release (Ca²⁺-Dependent Exocytosis):

  • SNARE proteins are targets for Botulinum & Tetanus toxins. ⚠️

⭐ ACh is released in discrete quanta. Each quantum (contents of one vesicle, ~5k-10k molecules) evokes a Miniature End-Plate Potential (MEPP).

Postsynaptic Events - Muscle's Spark

• ACh diffuses across synaptic cleft; 2 ACh molecules bind to α-subunits of nicotinic ACh receptors (nAChR) on the motor end plate.
• nAChR, a ligand-gated ion channel, opens:
  • Predominant Na+ influx, lesser K+ efflux.
• Causes local, non-propagated depolarization: End Plate Potential (EPP).
  • EPP is graded; its amplitude depends on the amount of ACh released.
• If EPP reaches threshold voltage (approx. -55mV), voltage-gated Na+ channels open.
• This triggers a propagated muscle fiber Action Potential (AP).
• AP initiates excitation-contraction coupling.
• ACh action is terminated by Acetylcholinesterase (AChE) hydrolysis in the synaptic cleft.

⭐ The End Plate Potential (EPP) is a graded, non-propagated potential; if it reaches threshold, it triggers a propagated muscle fiber action potential that leads to muscle contraction.

ACh Inactivation - Clearing the Cleft

• Mechanism: Rapid enzymatic hydrolysis of acetylcholine (ACh).
• Enzyme: Acetylcholinesterase (AChE).
  • Location: Synaptic cleft, anchored to basal lamina.
• Reaction: ACh $\xrightarrow{AChE}$ Choline + Acetate.
• Choline Fate: Actively reuptaken by presynaptic terminal (Na$^+$-Choline Transporter, ChT) for ACh resynthesis.
• Significance:
  • Terminates ACh signal promptly.
  • Enables muscle fiber repolarization and relaxation.
  • Prevents continuous stimulation & receptor desensitization.

⭐ Rapid hydrolysis of ACh by acetylcholinesterase is essential for timely muscle relaxation and repolarization of the endplate.

NMJ Clinical Aspects - Meds & Mayhem

• NMJ Blockers:
  • Depolarizing: Succinylcholine (fasciculations → paralysis).
  • Non-depolarizing: "-curoniums", "-curiums". Reversal: AChE inhibitors.
• Toxins/Poisons:
  • Organophosphates: AChE inhibition. 📌 DUMBBELS (Diarrhea, Urination, Miosis, Bronchospasm, Bradycardia, Emesis, Lacrimation, Salivation). Antidote: Atropine, Pralidoxime.
  • Botulinum toxin: Blocks ACh release.

⭐ Myasthenia Gravis: Autoimmune, antibodies vs. postsynaptic nAChRs, ↓ EPP amplitude, muscle weakness that worsens with use.

High‑Yield Points - ⚡ Biggest Takeaways

• Acetylcholine (ACh) is the primary neurotransmitter at the NMJ, binding to nicotinic ACh receptors (nAChR).
• Acetylcholinesterase (AChE) in the synaptic cleft rapidly hydrolyzes ACh, terminating its action.
• Presynaptic Ca2+ influx is essential for ACh vesicle release.
• The End Plate Potential (EPP) is a graded potential; if threshold is met, it initiates a muscle action potential.
• Myasthenia Gravis involves autoantibodies against nAChRs, reducing EPP amplitude and causing muscle weakness.
• Lambert-Eaton Syndrome features impaired ACh release due to antibodies against presynaptic Ca2+ channels.
• Botulinum toxin blocks ACh release; organophosphates and neostigmine inhibit AChE, prolonging ACh action.